Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05852730 · ClinicalTrials.gov registry record · Phase 2
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
A Phase 2 study of Motion Sickness, Space and Motion Simulation, sponsored by Repurposed Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05852730 is a Phase 2 study of Motion Sickness, Space and Motion Simulation that is actively recruiting participants, run by Repurposed Therapeutics. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05852730, a Phase 2 study of Motion Sickness, Space and Motion Simulation, is actively recruiting participants, sponsored by Repurposed Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary specific aim of this Field Test aim is to evaluate the feasibility and efficacy of administering the intranasal scopolamine gel in operational field settings using both astronaut and ground-control subjects that are exposed to provocative motion as part of their assigned duties. For the ground-control subjects, these may include motion simulations (e.g., centrifuge), parabolic flights and/or Orion capsule recovery operations. Astronaut participants may choose to test Inscop during provocative preflight training exercises (e.g., centrifugation), and can choose to take the medication prophylactically to prevent symptoms or after symptom onset to treat motion sickness during the launch and/or landing mission phases. Both ground-control and astronaut participants will be required to test the medication during a training session to monitor for adverse side effects. Participants in the field test aim will complete short debrief questionnaires to capture motion sickness symptoms, side effects, and feasibility comments. The investigators will also include field "control" subjects who did not take (INSCOP) to comment on what countermeasures subjects used and their effectiveness. The investigators will be recruiting astronaut participants from free-flier missions (e.g., SpaceX Polaris Dawn), Private Astronaut Missions (e.g., Axiom), and standard missions to the International Space Station.
Conditions Studied
Interventions
- DRUG DPI-386 Nasal Gel
- DRUG Other (e.g., promethazine, meclizine)
Study Locations (1)
Texas
- NASA Johnson Space Center Neuroscience Laboratory - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-08-10 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05852730
The ClinicalTrials.gov registry entry for NCT05852730 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repurposed Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Motion Sickness, Space appearing as the primary indexed condition, and to 2 interventions - of which DPI-386 Nasal Gel is the first listed.
NCT05852730 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05852730 about?
NCT05852730 is a clinical study titled "Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance". The primary specific aim of this Field Test aim is to evaluate the feasibility and efficacy of administering the intranasal scopolamine gel in operational field settings using both astronaut and ground-control subjects that are exposed to provocative motion as part of their assigned duties. For the ...
What is the current status of trial NCT05852730?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2021-08-10. Estimated completion is 2026-09.
What conditions does trial NCT05852730 study?
This clinical trial studies the following conditions: Motion Sickness, Space, Motion Simulation, Parabolic Flight.
What interventions are being tested in trial NCT05852730?
The interventions under investigation include: DPI-386 Nasal Gel (DRUG), Other (e.g., promethazine, meclizine) (DRUG).
Who is sponsoring clinical trial NCT05852730?
This trial is sponsored by Repurposed Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05852730 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Motion Sickness, Space
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.